Fund 3
New fund Vesalius Biocapital Fund 3

This new fund, launched in May 18th 2017, targets later-stage European life science companies in drug development, medtech, diagnostics and eHealth / mHealth.

Over €65 million of commitments secured

The fund secured over €65 million of commitments in a first closing in May 2017.


News for Vesalius Biocapital Fund 3

Fund 3 Announces First Close
read more